Sequence Real Customer Outcomes: An Evidence-Based Review

What Is Sequence and How Did It Become WeightWatchers Clinic?

Sequence launched in 2021 as a telehealth startup focused on prescribing GLP-1 receptor agonists for obesity. WeightWatchers (WW International) acquired Sequence in 2023 for approximately $132 million, folding it into what is now called WeightWatchers Clinic. The clinical workflow remained largely the same: patients complete an online intake, a licensed provider reviews their history, and eligible individuals receive prescriptions for FDA-approved anti-obesity medications.

The platform's provider network includes physicians, nurse practitioners, and physician assistants licensed in each patient's state. Visits are conducted asynchronously in most cases, with synchronous video available on request. WeightWatchers added its behavioral coaching layer on top of the original Sequence model, creating a hybrid of pharmacotherapy and lifestyle programming. Whether this hybrid actually improves outcomes beyond the drug effect alone is a question the company has not answered with published data.

What Medications Does Sequence Prescribe?

Sequence providers primarily prescribe two classes of GLP-1 receptor agonists: semaglutide and tirzepatide. Semaglutide 2.4 mg (Wegovy) received FDA approval for chronic weight management in June 2021. Tirzepatide (Zepbound), a dual GIP/GLP-1 receptor agonist, gained its obesity indication in November 2023.

Both drugs have strong Phase III data behind them. In STEP-1 (N=1,961), participants on semaglutide 2.4 mg lost a mean 14.9% of body weight at 68 weeks compared with 2.4% on placebo. The SURMOUNT-1 trial (N=2,539) showed tirzepatide at its highest dose (15 mg) produced 22.5% mean weight loss at 72 weeks versus 2.1% for placebo.

Sequence also prescribes ondansetron and other anti-nausea agents to manage the gastrointestinal side effects that cause roughly 40 to 50% of GLP-1 users to experience nausea during titration. Some providers on the platform have prescribed compounded semaglutide, though the FDA has raised safety concerns about compounded versions of these peptides.

Do Trial Results Translate to Real-World Sequence Patients?

This is the question that matters most, and the honest answer is: not perfectly. Clinical trials enroll motivated, closely monitored participants who receive the drug at no cost. Real-world patients face co-pay barriers, supply shortages, inconsistent follow-up, and the friction of daily life.

A 2024 retrospective cohort study published in JAMA Network Open (N=28,250) found that real-world semaglutide users lost a mean of 5.9% body weight at 12 months, considerably less than the 14.9% seen in STEP-1. The gap reflects adherence challenges: only about 30 to 40% of patients prescribed a GLP-1 for obesity remain on therapy at one year, according to data from IQVIA and reported by the Endocrine Society.

Sequence has not published its own retention or outcomes data in a peer-reviewed journal. The company's marketing materials cite patient testimonials showing 10 to 20% weight loss, but these represent self-selected success stories, not intention-to-treat analyses. Without platform-specific data on completion rates, average weight lost, or 12-month adherence, any claim about "Sequence outcomes" is really a claim about GLP-1 outcomes in general.

Dr. Caroline Apovian, a professor of medicine at Harvard Medical School and co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "Telehealth platforms can increase access to anti-obesity medications, but the key determinant of success is sustained adherence. The drug only works while you take it."

The Weight Regain Problem After Stopping

One of the most significant issues for any GLP-1 telehealth user is what happens after discontinuation. The STEP-1 extension trial published in Diabetes, Obesity and Metabolism showed that participants who stopped semaglutide after 68 weeks regained approximately two-thirds of their lost weight within the following year. Cardiometabolic improvements (HbA1c, blood pressure, lipid levels) also reversed.

This has direct implications for Sequence patients. If a patient loses 15% of body weight on semaglutide through the platform and then discontinues (due to cost, side effects, or supply issues), the expected trajectory is regain of roughly 10 percentage points of that loss within 12 months.

The 2023 American Gastroenterological Association guideline explicitly states: "Pharmacotherapy for obesity should be continued long-term, as discontinuation is associated with weight regain." This framing changes the cost calculus entirely. Sequence is not a short course of treatment. It is, for most patients, the beginning of an indefinite medication commitment.

How Much Does Sequence Actually Cost?

Sequence charges a membership fee of approximately $99 per month, which covers provider consultations, care coordination, and the platform's behavioral tools. That fee does not include the medication itself.

Brand-name semaglutide (Wegovy) carries a list price of approximately $1,349 per month, though actual out-of-pocket costs vary widely based on insurance coverage, manufacturer savings cards, and pharmacy benefit design. Tirzepatide (Zepbound) lists at roughly $1,060 per month. For patients with commercial insurance that covers anti-obesity medications, co-pays may range from $25 to $300 per month. For the uninsured or underinsured, the full list price makes sustained therapy financially unrealistic.

Sequence's cost structure compared with competitors looks like this:

| Platform | Monthly membership | Medication included? | Insurance billing? | |---|---|---|---| | Sequence / WW Clinic | ~$99 | No | Yes (coordination) | | Ro Body | ~$99-$145 | Compounded options available | Limited | | Hims/Hers | ~$199+ (with compound) | Compounded included | No | | Found | ~$129 | No | Yes (coordination) | | Direct PCP visit | Co-pay only | No | Yes |

The cheapest path for most patients remains a primary care physician who can prescribe Wegovy or Zepbound directly and bill insurance. Telehealth platforms add convenience and sometimes faster access, but they also add a membership layer that a traditional office visit does not require.

Is Sequence Legit? Evaluating the Clinical Model

Sequence operates within a legitimate medical framework. Its providers hold valid DEA and state medical licenses. Prescriptions are filled at licensed pharmacies. The drugs prescribed (semaglutide, tirzepatide) have FDA approval supported by large Phase III programs involving over 10,000 participants across the STEP and SURMOUNT trial families.

The concern is not legality but adequacy. The Obesity Medicine Association's 2024 clinical practice statement recommends that anti-obesity medication management include regular metabolic lab monitoring (fasting glucose, HbA1c, lipid panel, liver enzymes), screening for gallbladder disease (risk increases with rapid weight loss), assessment for lean mass preservation, and mental health screening.

Whether an asynchronous telehealth platform can deliver this level of monitoring is debatable. Some patients report thorough initial evaluations followed by increasingly brief check-ins. Others describe attentive ongoing care. The experience appears to vary by provider assignment.

Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has stated: "Telehealth expands the reach of obesity medicine, which is critical given that fewer than 2% of eligible patients currently receive pharmacotherapy. But it must not come at the expense of comprehensive metabolic monitoring."

Sequence vs. Alternatives: How It Compares

The telehealth weight loss market has grown crowded since 2022. Sequence's main differentiator was its early focus on insurance coordination for brand-name GLP-1s, setting it apart from platforms that rely primarily on compounded peptides.

Against Ro Body and Hims/Hers, Sequence offers a more insurance-oriented model. Ro and Hims have leaned into compounded semaglutide, which is cheaper out-of-pocket but raises questions about bioequivalence and sterility that the FDA has flagged repeatedly.

Against a traditional obesity medicine clinic, Sequence trades depth for convenience. An in-person obesity specialist might order a DEXA scan to track body composition, perform a physical exam to check for thyroid nodules or signs of Cushing syndrome, and refer for bariatric surgery evaluation if pharmacotherapy proves insufficient. Sequence's remote model cannot replicate these touchpoints.

The STEP-5 trial demonstrated that semaglutide maintained a 15.2% weight reduction at 104 weeks with continued use. The drug itself, not the delivery platform, drives the outcome. The relevant question for choosing between Sequence and alternatives is not "which platform produces better weight loss" but rather "which model best supports your ability to stay on therapy long-term."

Gastrointestinal Side Effects and Management

GLP-1 side effects are the primary reason patients discontinue therapy, and this matters for evaluating any platform that prescribes these drugs. In STEP-1, 44.2% of semaglutide-treated participants experienced nausea, 31.5% reported diarrhea, and 24.8% had vomiting. Most events were mild to moderate and occurred during dose escalation.

Sequence's protocol includes gradual dose titration (starting at 0.25 mg semaglutide weekly) and the option to prescribe anti-emetics. Patients who cannot tolerate semaglutide may be switched to tirzepatide, which showed a somewhat different GI profile in SURMOUNT-1: nausea rates of 24 to 33% depending on dose, lower than semaglutide's 44%.

Rare but serious adverse events include pancreatitis (incidence roughly 0.2 to 0.3% in trials), gallbladder events, and the theoretical thyroid C-cell tumor signal seen in rodent studies. The FDA's prescribing information for Wegovy carries a boxed warning regarding medullary thyroid carcinoma risk in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2.

What Happens When You Join Sequence: The Patient Experience

The onboarding process follows a standard telehealth workflow. Patients create an account, complete a medical history questionnaire, upload relevant lab work (or have labs ordered), and are matched with a provider. The provider reviews the case and, if appropriate, submits a prescription to a pharmacy.

Turnaround time from sign-up to prescription reportedly ranges from 48 hours to two weeks, depending on provider availability, insurance verification delays, and whether prior authorization is needed. Prior authorization for Wegovy or Zepbound can take anywhere from 3 to 21 business days, and denial rates remain high. A 2023 KFF survey found that roughly one in four prior authorization requests for GLP-1 medications was initially denied.

After the initial prescription, Sequence schedules follow-up check-ins (typically monthly), adjusts dosing, and provides access to the WeightWatchers behavioral program. The depth of ongoing monitoring depends largely on the individual provider's practice style within the platform.

Long-Term Considerations for Sequence Patients

Sustained GLP-1 therapy requires ongoing metabolic surveillance. The American Association of Clinical Endocrinology 2023 obesity algorithm recommends monitoring HbA1c, fasting lipids, and hepatic function at baseline and every 6 to 12 months. Patients losing weight rapidly (more than 1.5 kg per week) should be screened for gallstone formation with right upper quadrant ultrasound if symptomatic.

Lean mass loss is another concern. In STEP-1, approximately 39% of total weight lost was lean mass. Resistance training and adequate protein intake (1.2 to 1.6 g/kg/day per ESPEN guidelines) can mitigate this, but telehealth platforms vary in how aggressively they counsel patients on exercise and nutrition.

Patients considering Sequence should ask their provider three specific questions before starting: What is the plan for metabolic lab monitoring at 6 and 12 months? What is the discontinuation protocol if I need to stop? And what is the strategy for preserving lean mass during treatment?